Do analysts recommend HZD or 4BB?

4basebio has a consensus price target of GBX 1,400, suggesting a potential upside of 169.36%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is HZD or 4BB more profitable?

Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets Horizon Discovery Group plc (HZD.L) N/A N/A N/A 4basebio N/A -231.29% -54.30%

Is 4BB or PRTC more profitable?

4basebio has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% PureTech Health -2,355.32% -31.98% -13.39%

Do analysts recommend 4BB or VRP?

4basebio currently has a consensus target price of GBX 1,400, suggesting a potential upside of 169.36%. Given 4basebio's stronger consensus rating and higher probable upside, equities analysts clearly believe 4basebio is more favorable than Verona Pharma plc (VRP.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Verona Pharma plc (VRP.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is 4BB or VRP more profitable?

Verona Pharma plc (VRP.L)'s return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets 4basebio N/A -231.29% -54.30% Verona Pharma plc (VRP.L) N/A N/A N/A

Do analysts recommend ARIX or 4BB?

4basebio has a consensus target price of GBX 1,400, suggesting a potential upside of 169.36%. Given 4basebio's stronger consensus rating and higher possible upside, analysts clearly believe 4basebio is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 4basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better earnings & valuation, ARIX or 4BB?

Arix Bioscience has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arix Bioscience £14.16M 0.00 £14.96M £0.11 N/A 4basebio £1.69M 47.54 -£9.84M -£109.00 N/A

Which has stronger earnings and valuation, BTG or 4BB?

BTG has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BTG £159.40M 1.07 N/A £6.00 17.67 4basebio £1.69M 47.54 -£9.84M -£109.00 N/A

Is BTG or 4BB more profitable?

BTG's return on equity of 0.00% beat 4basebio's return on equity. Company Net Margins Return on Equity Return on Assets BTG N/A N/A N/A 4basebio N/A -231.29% -54.30%

4basebio (4BB) Competitors

GBX 519.75 -5.25 (-1.00%)

As of 07/31/2026 07:54 AM Eastern

Compare

4BB vs. HZD, PRTC, VRP, ARIX, and BTG

Should you buy 4basebio stock or one of its competitors? MarketBeat compares 4basebio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 4basebio include Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), and BTG (BTG). These companies are all part of the "biotechnology" industry.

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and 4basebio (LON:4BB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

0.9% of 4basebio shares are owned by institutional investors. 12.1% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A
4basebio	N/A	-231.29%	-54.30%

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A
4basebio	£1.69M	47.54	-£9.84M	-£109.00	N/A

In the previous week, Horizon Discovery Group plc (HZD.L)'s average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company	Overall Sentiment
Horizon Discovery Group plc (HZD.L)	Neutral
4basebio	Neutral

4basebio has a consensus price target of GBX 1,400, suggesting a potential upside of 169.36%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

4basebio beats Horizon Discovery Group plc (HZD.L) on 6 of the 10 factors compared between the two stocks.

How does 4basebio compare to PureTech Health?

4basebio (LON:4BB) and PureTech Health (LON:PRTC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, PureTech Health had 11 more articles in the media than 4basebio. MarketBeat recorded 11 mentions for PureTech Health and 0 mentions for 4basebio. PureTech Health's average media sentiment score of 1.35 beat 4basebio's score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.

Company	Overall Sentiment
4basebio	Neutral
PureTech Health	Positive

4basebio has higher earnings, but lower revenue than PureTech Health. 4basebio is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	47.54	-£9.84M	-£109.00	N/A
PureTech Health	£4.66M	62.24	-£91.86M	-£46.00	N/A

0.9% of 4basebio shares are owned by institutional investors. Comparatively, 33.5% of PureTech Health shares are owned by institutional investors. 12.1% of 4basebio shares are owned by company insiders. Comparatively, 13.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

4basebio presently has a consensus price target of GBX 1,400, suggesting a potential upside of 169.36%. PureTech Health has a consensus price target of GBX 508, suggesting a potential upside of 326.46%. Given PureTech Health's higher possible upside, analysts plainly believe PureTech Health is more favorable than 4basebio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

4basebio has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
PureTech Health	-2,355.32%	-31.98%	-13.39%

4basebio has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.793, suggesting that its share price is 21% less volatile than the broader market.

Summary

PureTech Health beats 4basebio on 11 of the 14 factors compared between the two stocks.

How does 4basebio compare to Verona Pharma plc (VRP.L)?

4basebio (LON:4BB) and Verona Pharma plc (VRP.L) (LON:VRP) are related small-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

In the previous week, 4basebio's average media sentiment score of 0.00 equaled Verona Pharma plc (VRP.L)'saverage media sentiment score.

Company	Overall Sentiment
4basebio	Neutral
Verona Pharma plc (VRP.L)	Neutral

4basebio currently has a consensus target price of GBX 1,400, suggesting a potential upside of 169.36%. Given 4basebio's stronger consensus rating and higher probable upside, equities analysts clearly believe 4basebio is more favorable than Verona Pharma plc (VRP.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Verona Pharma plc (VRP.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.9% of 4basebio shares are owned by institutional investors. 12.1% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Verona Pharma plc (VRP.L)'s return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4basebio	N/A	-231.29%	-54.30%
Verona Pharma plc (VRP.L)	N/A	N/A	N/A

Verona Pharma plc (VRP.L) has lower revenue, but higher earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4basebio	£1.69M	47.54	-£9.84M	-£109.00	N/A
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A

Summary

4basebio beats Verona Pharma plc (VRP.L) on 6 of the 10 factors compared between the two stocks.

How does 4basebio compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and 4basebio (LON:4BB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 0.9% of 4basebio shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by insiders. Comparatively, 12.1% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arix Bioscience has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
4basebio	£1.69M	47.54	-£9.84M	-£109.00	N/A

Arix Bioscience has a net margin of 105.64% compared to 4basebio's net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
4basebio	N/A	-231.29%	-54.30%

Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

4basebio has a consensus target price of GBX 1,400, suggesting a potential upside of 169.36%. Given 4basebio's stronger consensus rating and higher possible upside, analysts clearly believe 4basebio is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Arix Bioscience's average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company	Overall Sentiment
Arix Bioscience	Neutral
4basebio	Neutral

Summary

Arix Bioscience beats 4basebio on 9 of the 13 factors compared between the two stocks.

How does 4basebio compare to BTG?

BTG (LON:BTG) and 4basebio (LON:4BB) are related small-cap companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

19.2% of BTG shares are owned by institutional investors. Comparatively, 0.9% of 4basebio shares are owned by institutional investors. 19.7% of BTG shares are owned by company insiders. Comparatively, 12.1% of 4basebio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BTG has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BTG	£159.40M	1.07	N/A	£6.00	17.67
4basebio	£1.69M	47.54	-£9.84M	-£109.00	N/A

In the previous week, BTG had 3 more articles in the media than 4basebio. MarketBeat recorded 3 mentions for BTG and 0 mentions for 4basebio. BTG's average media sentiment score of 0.34 beat 4basebio's score of 0.00 indicating that BTG is being referred to more favorably in the media.

Company	Overall Sentiment
BTG	Neutral
4basebio	Neutral

BTG's return on equity of 0.00% beat 4basebio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BTG	N/A	N/A	N/A
4basebio	N/A	-231.29%	-54.30%

BTG currently has a consensus price target of GBX 160, suggesting a potential upside of 50.94%. 4basebio has a consensus price target of GBX 1,400, suggesting a potential upside of 169.36%. Given 4basebio's higher possible upside, analysts plainly believe 4basebio is more favorable than BTG.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
4basebio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

BTG beats 4basebio on 10 of the 12 factors compared between the two stocks.

Get 4basebio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding 4BB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

4BB vs. The Competition

Export

Metric	4basebio	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£81.30M	£3.55B	£7.17B	£2.79B
Dividend Yield	N/A	3.78%	2.59%	6.15%
P/E Ratio	-4.77	7.38	282.25	368.29
Price / Sales	47.54	1,266.83	587.75	83,501.30
Price / Cash	16.08	44.80	28.60	27.89
Price / Book	-12.68	16.78	10.93	7.04
Net Income	-£9.84M	-£12.56M	£3.50B	£5.89B
7 Day Performance	N/A	-1.47%	-0.24%	6.43%
1 Month Performance	3.85%	-8.45%	-3.70%	0.02%
1 Year Performance	-47.45%	48.32%	61.98%	63.72%

4basebio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
4BB 4basebio	N/A	GBX 519.75 -1.0%	GBX 1,400 +169.4%	-47.4%	£81.30M	£1.69M	N/A	101	Gap Down
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	3.4302 of 5 stars	GBX 123 -0.3%	GBX 508 +313.0%	-13.7%	£299.40M	£4.66M	N/A	300	News Coverage Gap Down
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:4BB) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4basebio (4BB) Competitors

4BB vs. HZD, PRTC, VRP, ARIX, and BTG

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does 4basebio compare to PureTech Health?

Summary

How does 4basebio compare to Verona Pharma plc (VRP.L)?

Summary

How does 4basebio compare to Arix Bioscience?

Summary

How does 4basebio compare to BTG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

4BB vs. The Competition

4basebio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4basebio (4BB) Competitors

4BB vs. HZD, PRTC, VRP, ARIX, and BTG

How does 4basebio compare to Horizon Discovery Group plc (HZD.L)?

Do institutionals & insiders have more ownership in HZD or 4BB?

Is HZD or 4BB more profitable?

Which has stronger earnings & valuation, HZD or 4BB?

Does the media refer more to HZD or 4BB?

Do analysts recommend HZD or 4BB?

Summary

How does 4basebio compare to PureTech Health?

Does the media prefer 4BB or PRTC?

Which has better valuation & earnings, 4BB or PRTC?

Do insiders & institutionals have more ownership in 4BB or PRTC?

Do analysts recommend 4BB or PRTC?

Is 4BB or PRTC more profitable?

Which has more volatility & risk, 4BB or PRTC?

Summary

How does 4basebio compare to Verona Pharma plc (VRP.L)?

Does the media favor 4BB or VRP?

Do analysts recommend 4BB or VRP?

Do insiders and institutionals have more ownership in 4BB or VRP?

Is 4BB or VRP more profitable?

Which has higher earnings and valuation, 4BB or VRP?

Summary

How does 4basebio compare to Arix Bioscience?

Do institutionals & insiders have more ownership in ARIX or 4BB?

Which has better earnings & valuation, ARIX or 4BB?

Is ARIX or 4BB more profitable?

Which has more volatility and risk, ARIX or 4BB?

Do analysts recommend ARIX or 4BB?

Does the media refer more to ARIX or 4BB?

Summary

How does 4basebio compare to BTG?

Do institutionals and insiders have more ownership in BTG or 4BB?

Which has stronger earnings and valuation, BTG or 4BB?

Does the media prefer BTG or 4BB?

Is BTG or 4BB more profitable?

Do analysts recommend BTG or 4BB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

4BB vs. The Competition

4basebio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools